Duxbury Mark S, Ito Hiromichi, Zinner Michael J, Ashley Stanley W, Whang Edward E
Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Am Coll Surg. 2004 Jun;198(6):953-9. doi: 10.1016/j.jamcollsurg.2004.01.037.
The c-Src tyrosine kinase is a determinant of malignant cellular behavior in a variety of human cancers. We sought to determine the effect of suppressing c-Src expression on pancreatic adenocarcinoma chemosensitivity to gemcitabine.
PANC1, MIAPaCa2, BxPC3, and Capan2 pancreatic adenocarcinoma cell lines were studied. Expression of c-Src was determined by Western blot analysis. c-Src kinase activity was determined by in vitro kinase assay. RNA interference was used to suppress c-Src expression. Gemcitabine-induced cytotoxicity was determined by tetrazolium reduction assay and caspase profiling was performed. The effect of Src-specific siRNA on Akt activity was quantified.
Src expression and kinase activity in cell lines were directly correlated with gemcitabine chemoresistance. c-Src-specific siRNA suppressed c-Src expression and kinase activity. c-Src-specific siRNA increased gemcitabine-induced, caspase-mediated apoptosis. Akt activity was decreased by suppression of c-Src expression.
c-Src is a determinant of pancreatic adenocarcinoma chemoresistance and represents a potential target for therapeutic intervention.
c-Src酪氨酸激酶是多种人类癌症中恶性细胞行为的一个决定因素。我们试图确定抑制c-Src表达对胰腺腺癌吉西他滨化疗敏感性的影响。
对PANC1、MIAPaCa2、BxPC3和Capan2胰腺腺癌细胞系进行研究。通过蛋白质免疫印迹分析确定c-Src的表达。通过体外激酶测定确定c-Src激酶活性。使用RNA干扰抑制c-Src表达。通过四氮唑还原测定确定吉西他滨诱导的细胞毒性,并进行半胱天冬酶分析。对Src特异性小干扰RNA对Akt活性的影响进行定量。
细胞系中Src的表达和激酶活性与吉西他滨化疗耐药性直接相关。c-Src特异性小干扰RNA抑制c-Src表达和激酶活性。c-Src特异性小干扰RNA增加吉西他滨诱导的、半胱天冬酶介导的细胞凋亡。抑制c-Src表达可降低Akt活性。
c-Src是胰腺腺癌化疗耐药性的一个决定因素,是治疗干预的一个潜在靶点。